2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6000 MAGIC composite score predicts outcomes of second-line therapy for acute graft-versus-host disease

Tara Sebastian, MD, Daniela Weber2, Aaron Etra, MD3, Ingrid Vasova4, Francis Ayuketang Ayuk, MD5, Hannah Choe, MD6, Zachariah Defilipp, MD7, Francesco Quagliarella, MD8, Karni Bedirian9, Marcio Augusto Diniz, PhD10, Paibel Aguayo-Hiraldo, MD11, Peter Bader Sr, MD, PhD12, Janna Baez13, Chantiya Chanswangphuwana, MD14, Gilbert Eng15, Thomas Francke16, Elizabeth Hexner, MD17, Nikolaos Katsivelos18, Carrie Kitko, MD19, Sabrina Kraus, MD20, Ioannis Evangelos Louloudis, MD21, George Morales22, Ryotaro Nakamura, MD23, Timothy S. Olson, MD, PhD24, Muna Qayed, MD, MSc25, Pavan Reddy, MD26, Ran Reshef, MD, MSc27, Tal Schechter-Finkelstein, MD28, Tingyu Wang29, Matthias Woelfl30, Rachel Young31, Robert Zeiser, MD, PhD32, William Hogan, M.B., B.Ch.33, John Levine, MD, MS34, James Ferrara, MD, DSc35
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 University of Regensburg, Regensburg, Germany
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany
5 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 Massachusetts General Hospital, Boston, United States
8 Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
9 Icahn School of Medicine at Mount Sinai, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, United States
11 Children's Hospital Los Angeles, Los Angeles, United States
12 Goethe University, Frankfurt, Germany
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Hannover Medical School, Hannover, Germany
17 Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
18 Icahn School of Medicine at Mount Sinai, New York, New York, United States
19 Vanderbilt University Medical Center, Nashville, United States
20 University Hospital of Würzburg, Würzburg, Germany
21 Icahn School of Medicine at Mount Sinai, New York, New York, United States
22 Icahn School of Medicine at Mount Sinai, New York, New York, United States
23 City of Hope, Duarte, United States
24 Children's Hospital of Philadelphia, Philadelphia, United States
25 Emory University School of Medicine, Atlanta, United States
26 Dan Duncan Cancer Center, Baylor College of Medicine, Houston, United States
27 Columbia University Irving Medical Center, New York, United States
28 The Hospital for Sick Children, Toronto, Canada
29 Icahn School of Medicine at Mount Sinai, New York, New York, United States
30 Children's Hospital, University Hospital of Würzburg, Würzburg, Germany
31 Icahn School of Medicine at Mount Sinai, New York, New York, United States
32 University of Freiburg Medical Center, Freiburg, Germany
33 Mayo Clinic, Rochester, United States
34 Icahn School of Medicine at Mount Sinai, New York, New York, United States
35 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background:
Acute graft versus host disease (GVHD) is a potentially lethal complication of hematopoietic cell transplantation (HCT). Standard first-line therapy is high-dose corticosteroids, but around 30% of patients develop steroid-refractory GVHD and have very poor outcomes. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, has become the standard of care for steroid-refractory acute GVHD, but it is unclear which patients derive benefit. Traditional GVHD risk stratification is based on clinical criteria alone. Ann Arbor (AA) scores, which combine two serum biomarkers, ST2 and REG3a, act as a liquid biopsy of gastrointestinal crypt damage and also consistently stratify risk. Akahoshi et al. validated the MAGIC composite score (MCS) at first-line treatment which integrates clinical severity with AA scores as a more accurate predictor of outcomes than clinical symptoms alone (Blood, 2024). The utility of MCS at second-line treatment has not been evaluated.

Methods:
We analyzed clinical data and biomarker samples of patients who required second-line treatment for grade II-IV GVHD after first-line treatment with steroids. MCS 1-3 were calculated according to the methods of Akahoshi et al. The primary outcome was 12-month non-relapse mortality (NRM); survival at 12 months and clinical response at day (D) 28 were also assessed.

Results:
MCS scores were calculated for 278 patients who received second-line therapy for grade II-IV GVHD after first-line steroids and had serum samples available for biomarker analysis. Most patients received second-line therapy for grade III/IV GVHD (184/278, 66%), and the vast majority had lower GI involvement (209/278, 75%). Approximately half of patients received ruxolitinib-based therapy as second-line treatment (147/278, 53%). Acute GVHD accounted for 77% of the deaths within 1 year of second-line therapy and relapse accounted for 7%.

Patients were first categorized by clinical risk as grade II or grades III/IV. As expected, higher clinical risk corresponded with higher 12-month NRM (61% vs. 28%, p<0.001) and worse 12-month survival (37% vs. 65%, p<0.001). With the integration of biomarkers and clinical risk, NRM for each clinical risk group increased as the AA score increased. Conversely, NRM also increased within a given AA score as clinical symptoms became more severe. As a result of integration, 34/278 (12%) patients were classified as MCS1, 143/278 (51%) as MCS2, and 101/278 (37%) as MCS3. Each MCS group had a distinct risk of NRM and survival. The incidence of 12-month NRM significantly increased with each increase in MCS (16%, 41%, and 73%, respectively; p<0.001), and the probability of 12-month survival significantly decreased (77%, 56%, and 24%, respectively; p<0.001). The area under the receiver operating characteristic curve (AUROC) for 12-month NRM was significantly higher in the MCS model than in the clinical grade model (0.70 vs. 0.63; p=0.023). 

We next evaluated D28 response to second-line therapy. Increased clinical grade was associated with a 20% decrease in complete and overall response. Once again, MCS created three risk categories with decreasing probability of D28 complete response (47%, 38%, and 20%, respectively; p=0.001) and overall response (68%, 58%, and 44%, respectively; p=0.02).

Ruxolitinib has become the standard of care for second-line treatment. We therefore evaluated the MCS model in the subset of patients who received ruxolitinib (n=147). In this important subset, MCS classification again created three distinct groups with increasing 12-month NRM (13%, 37%, and 67%, respectively; p=0.002) and decreasing D28 CR (60%, 44%, and 19%, respectively; p=0.003).  

Conclusion:
The integration of clinical symptoms and serum biomarkers created an MCS model that stratified 278 patients with steroid-refractory GVHD into three risk groups with significantly different NRM, survival outcomes, and response rates. The MCS provided a significantly more accurate prediction of NRM than clinical criteria alone. Most patients requiring second-line treatment are categorized as MCS2/3 and have poor outcomes despite receiving standard-of-care ruxolitinib, underscoring the need for novel therapies in this group. The MCS may be of use as an eligibility criterion for future clinical trials in this high-risk population.

Tara Sebastian, MD: No relevant conflicts of interest to declare.